GlobeNewswire

#DeleteFacebook - VPN.com Takes Protest of Cambridge Analytica Scandal to U.S. Capitol & Facebook's Headquarters

Dela

WASHINGTON and SAN FRANCISCO and AUSTIN, Texas, April 09, 2018 (GLOBE NEWSWIRE) -- VPN.com is taking the fight for privacy and security directly to Facebook's doorsteps and the U.S. Capitol. The company has organized protests in multiple major cities (Washington, D.C., San Francisco and Austin) to advocate for consumer privacy rights and online security.

The peaceful protests are expected to attract thousands, and will feature local and national news coverage. VPN.com will be on site with at least a half-dozen 24-foot box trucks at the U.S. Capitol, Facebook's Headquarters and its Austin campus to represent the will of the people by displaying: #DeleteFacebook and #OurPrivacyMatters on the sides of each truck.

  • #DeleteFacebook Protest at the U.S. Senate Judiciary and Commerce Committees Joint Hearing
    • Date: Tuesday April 10, 2018 - starting at 1pm EDT
    • Address: First St. NE, Washington, DC 20515
    • Location: Outside the U.S. Capitol Visitors Center
       
  • #DeleteFacebook Protest at the U.S. Energy and Commerce Committee Hearing
    • Date: Wednesday April 11, 2018 - starting at 9am EDT
    • Address: 45 Independence Ave SW, Washington, DC 20515
    • Location: Outside the Rayburn House Office Building
       
  • #DeleteFacebook Protest at Facebook Headquarters
    • To Be Determined

As an organization fighting for consumer privacy and security rights across the globe, VPN.com has already put the CEO of Netflix, Reed Hastings, on notice. His unwillingness to remove the current Netflix VPN ban requires customers to choose between their privacy and entertainment; Hastings also happens to sit on Facebook's Board of Directors. VPN.com believes this reinforces the need to have a voice for consumers' privacy rights.

The unprecedented #DeleteFacebook protests follow in the wake of the Cambridge Analytica Scandal-which has resulted in the unauthorized dissemination and unconsented use of the private data of more than 87 million accounts-with the potential exposure affecting as many as 2 billion profiles; or approximately the entire user base of Facebook.

In the aftermath, globally recognized names-which include Mozilla, Tesla, Elon Musk and WhatsApp co-founder Brian Acton-have deleted their Facebook accounts. The list continues to grow each minute across all products and services that the company offers.

Michael Gargiulo, CEO of VPN.com, asks three important questions that all consumers should take seriously:

"Facebook has known about this particular breach for at least 861 days and is likely trying to disclose the damage now only because this scandal has just been revealed. What other breaches have occurred since then? What did insiders know about these breaches? And did they make trades of Facebook stock based on this information?"

"The goal of our #DeleteFacebook campaign is to raise awareness about the true costs of using free, unregulated platforms and services like Facebook that can expose your private information," he adds. "Tragically, millions of Americans are clueless as to how their data is being used, even in light of this and other recent breaches."

For more information on #DeleteFacebook, #OurPrivacyMatters and deleting your Facebook profile, please visit: https://vpn.com/facebook

For media inquiries, please email: pr@vpn.com
For phone inquiries, please call: (855) 876-3278

About VPN.com

VPN.com is the worldwide leader in Virtual Private Network (VPN) research and statistics. The company has collected 188,000 data points spanning more than 900 VPN providers, giving people the only way to quickly review and compare hundreds of VPN services at once. VPN.com's mission is to help 1 billion people protect their privacy online by 2025. The company aims to accomplish this through transparent research and by fighting for privacy rights across the globe.

Find your VPN today at: https://www.vpn.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VPN.com via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum